<?xml version="1.0" encoding="UTF-8"?>
<p>After the clinical studies of a MD, a risk management file must be developed for the post-market surveillance, including results from the risk-benefit analysis and risk minimisation measures. The risk management file should contain definitions of possible hazardous situation associated to the use of the investigated MD and all the possible applicable risk minimisation measures for patients as well as healthcare personnel. This includes the risk analysis, risk evaluation, the implementation and verification of the risk control measures and the final assessment of the acceptability of residual risks [
 <xref rid="B130-materials-13-04532" ref-type="bibr">130</xref>].
</p>
